These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2491287)

  • 41. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant intralesional and systemic Corynebacterium parvum immunotherapy for surgically treated head and neck cancer.
    Beatty JD; Terz JJ; Brown PW; Lawrence W; Schuller GB; Kaplan AM
    Surg Forum; 1978; 29():155-7. PubMed ID: 401122
    [No Abstract]   [Full Text] [Related]  

  • 43. Evidence for granulocyte-mediated macrophage activation after C. parvum immunization.
    Chapes SK; Haskill S
    Cell Immunol; 1983 Feb; 75(2):367-77. PubMed ID: 6831566
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Histopathological aspects and macrophage reactivity in rats with Guerin's T8 viral tumor after treatment with Corynebacterium parvum].
    Caruso R; Bonina L; Chimicata S; Iannello D; Inferrera C; Mastroeni P
    Arch De Vecchi Anat Patol; 1979 Mar; 63(3):491-9. PubMed ID: 262125
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of rat fibrosarcoma by radiotherapy plus immune adjuvant.
    Moroson H; Schechter M
    Biomedicine; 1976 May; 25(3):97-100. PubMed ID: 949523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase-II trial of Corynebacterium parvum as adjuvant to surgery in the treatment of operable lung cancer.
    Woodruff M; Walbaum P
    Cancer Immunol Immunother; 1983; 16(2):114-6. PubMed ID: 6362846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Corynebacterium parvum vaccine in conjunction with immunosuppression in renal transplant in dogs.
    Munda R; Alexander JW; Stinnett JD; Weiss MA; Morris MJ
    Transplantation; 1982 Mar; 33(3):333-5. PubMed ID: 7039044
    [No Abstract]   [Full Text] [Related]  

  • 48. Improved survival after pneumococcus in splenectomized and nonsplenectomized mice with Corynebacterium parvum.
    Hebert JC; Gamelli RL; Foster RS; Chalmer BJ; Davis JH
    Arch Surg; 1983 Mar; 118(3):328-32. PubMed ID: 6824432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunopotentiation of cell-mediated hypersensitivity by Corynebacterium parvum (Propionibacterium acnes).
    Maguire HC; Cipriano D
    Int Arch Allergy Appl Immunol; 1983; 70(1):34-9. PubMed ID: 6848475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of soluble mediators generated during growth of the Landschütz ascites carcinoma on the chemotaxis of normal and Corynebacterium parvum-stimulated peritoneal leucocytes.
    McIntosh LC; Thomson AW
    Br J Exp Pathol; 1984 Aug; 65(4):441-51. PubMed ID: 6466553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of normal rat macrophage functions by soluble tumor products. Effect of systemic treatment with bacterial immunomodulators.
    Iannello D; Bonina L; Delfino D; Berlinghieri MC; Mastroeni P
    Cancer Immunol Immunother; 1984; 17(1):38-41. PubMed ID: 6428737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-dependent macrophage stimulation by Corynebacterium parvum.
    Loose LD; Astry CL; Megirian R
    J Immunopharmacol; 1980; 2(3):349-65. PubMed ID: 6821558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mouse neoplasia and immunity: effects of radiation, hyperthermia, 2-deoxy-D-glucose, and Corynebacterium parvum.
    Gridley DS; Nutter RL; Kettering JD; Mantik DW; Slater JM
    Oncology; 1985; 42(6):391-8. PubMed ID: 4069554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The quantity and function of pulmonary alveolar macrophages after splenectomy and Corynebacterium parvum.
    Cioffi WG; Hebert JC; Gamelli RL; Foster RS
    J Trauma; 1985 May; 25(5):405-9. PubMed ID: 3999160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The complications of intravenous Corynebacterium parvum infusion.
    Gill PG; Morris PJ; Kettlewell M
    Clin Exp Immunol; 1977 Nov; 30(2):229-32. PubMed ID: 606444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Active, specific immunotherapy of murine leukemia. II. Adjuvant effect of Corynebacterium parvum.
    Bartlett GL; Kreider JW
    Int J Cancer; 1979 Nov; 24(5):636-43. PubMed ID: 528079
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Malignant angioendothelioma--effect of immunotherapy with Corynebacterium parvum.
    Tan SG; Cotterill JA; Roberts MM; Cunliffe WJ
    Acta Derm Venereol; 1978; 58(6):551-3. PubMed ID: 83086
    [No Abstract]   [Full Text] [Related]  

  • 58. Nonspecific immunotherapy by Corynebacterium parvum: phase I toxicity study in 12 patients with advanced cancer.
    Cheng VS; Suit HD; Wang CC; Cummings C
    Cancer; 1976 Apr; 37(4):1687-95. PubMed ID: 769937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. C. parvum treatment of transplanted rat tumours of spontaneous origin.
    Willmott N; Pimm MV; Baldwin RW
    Int J Cancer; 1979 Sep; 24(3):323-8. PubMed ID: 385514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study of a multi-modal schedule with Corynebacterium parvum.
    McIntosh IH; Thynne GS; Bejrajati P; Walsh G; Greening WP
    Dev Biol Stand; 1977 Apr 13-15; 38():477-82. PubMed ID: 344102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.